1. Home
  2. NVTS vs MLYS Comparison

NVTS vs MLYS Comparison

Compare NVTS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Navitas Semiconductor Corporation

NVTS

Navitas Semiconductor Corporation

HOLD

Current Price

$9.07

Market Cap

2.5B

Sector

Technology

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$23.85

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVTS
MLYS
Founded
2014
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.4B
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
NVTS
MLYS
Price
$9.07
$23.85
Analyst Decision
Buy
Strong Buy
Analyst Count
5
6
Target Price
$6.68
$48.67
AVG Volume (30 Days)
17.6M
973.7K
Earning Date
05-25-2026
06-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.43
EPS
N/A
N/A
Revenue
$45,916,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$77.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.52
$10.44
52 Week High
$17.79
$47.65

Technical Indicators

Market Signals
Indicator
NVTS
MLYS
Relative Strength Index (RSI) 48.91 29.67
Support Level $9.03 $13.42
Resistance Level $9.23 $31.09
Average True Range (ATR) 0.81 1.78
MACD 0.08 -0.23
Stochastic Oscillator 32.23 3.38

Price Performance

Historical Comparison
NVTS
MLYS

About NVTS Navitas Semiconductor Corporation

Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components. Geographically, the company operates in Hong Kong, China, Europe, the United States, Rest of Asia, and Others. The majority of revenue is generated from Hong Kong.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: